


Dynamin-1 and Epilepsy

How autosomal dominant **Dynamin-1** variants disrupt synaptic vesicle recycling and lead to epilepsy.

Dynamin-1 is a GTPase that oligomerizes to form a necklace-like ring around presynaptic vesicles to excise them from the membrane during endocytosis.




Dynamin-1 (GTPase)

Oligomerizes into a ring (necklace) that wraps around budding vesicles to pinch them off and recycle membrane for the next signal.



Action potential arrives

Neurotransmitter binds receptors



Signal transmitted to the next neuron




Swipe to learn how **DNM1** variants can act in an autosomal dominant manner

Most disease-causing *DNM1* variants are *heterozygous*, *de novo* and act in an autosomal dominant manner.

Wild type


Chromosome 9



Both *DNMT1* copies are normal.

Heterozygous *DNMT1* variant

Chromosome 9



One **altered** copy (heterozygous) can be enough to disrupt function.



Most disease-causing *DNMT1* variants are **heterozygous** and arise **de novo** (new in the child), meaning they are usually not inherited from a parent.



Predicted global incidence of DNM1-DEE

According to López-Rivera et al. (Brain, 2020), *DNM1*-associated neurodevelopmental disorders caused by *de novo* variants are predicted to occur in about 3.78 per 100,000 births.



3.78 in 100,000 births

Predicted incidence worldwide

Supplementary spreadsheet value for *DNM1*: 3.78198 per 100,000 births



**~5,000
new cases/year
worldwide**

Approximate projected
annual births affected
worldwide

Observed patient sources (July 2025)

177

**DNM1 Global
Community**
(Facebook group)



79

GeneDx



27

Labcorp



>70

**Clinical
publications**



These sources may overlap and should not be
interpreted as unique patients.

Total >250 identified individuals



Oldest reported individual is around 33 years old.



**Still
underdiagnosed**

Diagnosis is increasing
as exome/genome
sequencing becomes
more widely used
globally.



SCN1A / Dravet syndrome

7.21

DNM1

3.78

DNM1 is about half the
predicted incidence of
Dravet syndrome in the
same catalogue.



How this estimate was generated

This is a model-based estimate from López-Rivera et al. It was inferred from *de novo* variant data in large sequencing cohorts and gene-specific mutational models / variant-intolerance metrics. It is not a direct population-based epidemiology estimate from newborn screening, registries, or complete case counting.



Why this estimate is useful

These modeled estimates help approximate the expected birth incidence of *DNM1-DEE*, especially for an underdiagnosed disorder.

Source: López-Rivera et al., Brain (2020)
doi.org/10.1093/brain/awaa051



Takeaway: Even though only a fraction of patients are currently recognized, the predicted birth incidence suggests *DNM1-DEE* is substantially underdiagnosed worldwide.



Swipe to learn more about the ClinVar landscape of *DNM1* variants

ClinVar landscape of DNM1 variants



ClinVar tracks submitted variants and their interpretations; these counts do not represent unique patients.



ClinVar variation search snapshot for:

DNM1[*gene*] AND single gene[*PROP*]



906

total ClinVar results




398

results with molecular consequence annotation

ClinVar graphical view (*DNM1* on GRCh37)

DNM1



Takeaway

ClinVar shows a broad spectrum of *DNM1* variants across the gene, including pathogenic / likely pathogenic variants and variants of uncertain significance.



Why this matters

ClinVar helps families, clinicians and researchers track known *DNM1* variants, interpretation categories and reported molecular consequences.




Source: ClinVar Variation Search (NCBI)
ncbi.nlm.nih.gov/clinvar/search



Swipe to learn about *Dynamin-1's* specialized domains

Dynamin-1 has specialized domains

Dynamin-1 is a large GTPase built from five domains, each with a unique job.



Together, these domains allow Dynamin-1 to oligomerize into a necklace-like collar wraps around presynaptic vesicle necks and excises vesicles during recycling.




Swipe to learn how missense mutations can disrupt ***DNM1*** protein structure


Most pathogenic *DNM1* variants are missense mutations.

A missense mutation is a one-letter DNA change that alters one amino acid in the protein.


1 DNA point mutation



2 DNA to mRNA to protein translation



3 3D *DNM1* protein structure



Because protein shape determines function, even a single amino acid change can impair *DNM1* activity.




Swipe to learn about the most recurrent *DNM1* variants

Most recurrent *DNM1* variants

R237W and c.1197-8G>A together account for about **30%** of *DNM1* developmental and epileptic encephalopathy (DEE) cases.

1 R237W (GTPase domain)


Exonic point mutation



- Single base change in an exon
- Changes one amino acid in the GTPase domain

2 c.1197-8G>A (splice acceptor / middle domain)

Intronic splice-site variant



- Intronic variant affects the splice acceptor
- Adds amino acids and destabilizes the middle domain




Although one variant is **exonic** and the other is **intronic**, both disrupt *DNM1* protein function and contribute to severe *DNM1-DEE*.

Mutant DNM1 destabilizes the oligomer


Mutant *DNM1* can incorporate into the oligomer and interfere with the whole protein complex, creating a **dominant-negative effect**.

WT oligomer



- ✓ Stable complex
- ✓ Efficient vesicle scission and recycling

WT + mutant oligomer



- ✗ Destabilized complex
- ✗ Dysfunctional vesicle fission / recycling




By disrupting the oligomer's stability, **mutant DNM1** impairs vesicle fission, undermining synaptic recycling and neuronal signaling.



Swipe to learn how impaired recycling can lead to epilepsy

Impaired recycling can lead to epilepsy



This results in DNM1 Developmental and Epileptic Encephalopathy

Hallmark phenotype:

- Infant-onset epilepsy
- Epilepsy mainly infantile spasms, frequently evolving to Lennox–Gastaut syndrome
- Severe to profound intellectual disability
- Hypotonia


Therapeutic strategies under development for DNM1-DEE

Four therapeutic approaches are being explored to reduce the effects of pathogenic *DNM1* variants.



1. Allele-specific ASO

Most advanced personalized approach




SNP-based allele-specific ASO

- Direct allele-specific ASO
- SNP-based allele-specific ASO
- **Goal:** selectively lower the mutant transcript while preserving the healthy copy
- **Status:** ongoing personalized / n-of-1 therapy development



2. Base editing

Personalized / n-of-1 concept




- Aims to directly correct selected pathogenic variants at the DNA level
- Best suited to specific variants
- **Status:** under development



3. Drug repurposing

Academic preclinical



- Bonnycastle et al., 2023 identified BMS-204352 as a promising repurposing candidate
- In a *DNM1* mouse model, it accelerated endocytosis and reversed cell, circuit and seizure phenotypes
- **Status:** academic preclinical



4. Knockdown-replace gene therapy

Preclinical proof of concept



- Combines knockdown of *DNM1* with delivery of an RNAi-resistant healthy copy
- In a mouse model, this strategy improved survival, growth and synaptic function
- **Status:** preclinical proof of concept



Swipe to see selected references and resources

Selected references & resources

Key sources used throughout this DNM1 visual guide

- 1 **Daumke Lab (MDC Berlin) — 3D dynamin**
mdc-berlin.de/daumke
- 2 **DNM1 research publications database**
clinical cases included
dnm1epilepsy.org/professionals
- 3 **Helbig team — latest publication**
pmc.ncbi.nlm.nih.gov/articles/PMC13086092/
- 4 **Orphanet — DNM1 gene page**
orpha.net
- 5 **ClinVar — DNM1 variation search**
- 6 **Human DNM1 3D structures**
dnm1epilepsy.org/drugdevelopers_under_professionals
- 7 **OMIM — DNM1 (602377)**
omim.org/entry/602377
- 8 **GeneCards — DNM1**
genecards.org/card/DNM1
- 9 **GenCC submission SGC-119874.1**
thegencc.org
- 10 **Ensembl — ENSG00000106976**
ensembl.org



Additional resources and updates:
dnm1epilepsy.org



rare dynamos
THERAPIES | RESEARCH
GLOBAL COMMUNITY **DNM1 EPILEPSY**